<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02411500</url>
  </required_header>
  <id_info>
    <org_study_id>CP734-1003</org_study_id>
    <nct_id>NCT02411500</nct_id>
  </id_info>
  <brief_title>A Pharmacokinetic, Safety and Tolerability Study in Healthy Adult Males</brief_title>
  <official_title>A Randomized, Open Label, Four Period, Cross-Over Study to Evaluate the Pharmacokinetics of Single Doses of Various TRV734 Formulations in Healthy Male Subjects</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Trevena Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Trevena Inc.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The primary objective of this study is to evaluate the pharmacokinetics of various TRV734
      formulations in healthy male subjects.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>February 2015</start_date>
  <completion_date type="Actual">March 2015</completion_date>
  <primary_completion_date type="Actual">March 2015</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Evaluate the maximum observed plasma concentration (Cmax)</measure>
    <time_frame>9-days</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Evaluate the time at which the maximum plasma concentration was observed (tmax)</measure>
    <time_frame>9-days</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Evaluate the area under the plasma concentration-time curve from time 0 to the last measurable plasma concentration (AUC0-t)</measure>
    <time_frame>9-days</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Evaluate the area under the plasma concentration-time curve from time 0 to time extrapolated to infinity (AUC0-inf)</measure>
    <time_frame>9-days</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Evaluate the apparent elimination half-life (t1/2)</measure>
    <time_frame>9-days</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Evaluate the apparent clearance (CL/F)</measure>
    <time_frame>9-days</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Safety and tolerability as measured by adverse events</measure>
    <time_frame>9-days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Safety and tolerability as measured by clinical observations</measure>
    <time_frame>9-days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Safety and tolerability as measured by 12-lead ECGs</measure>
    <time_frame>9-days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Safety and tolerability as measured by cardiac telemetry monitoring</measure>
    <time_frame>9-days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Safety and tolerability as measured by vital signs (BP, HR, RR and oral temperature)</measure>
    <time_frame>9-days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Safety and tolerability as measured by oxygen saturation</measure>
    <time_frame>9-days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Safety and tolerability as measured by safety laboratory tests</measure>
    <time_frame>9-days</time_frame>
  </secondary_outcome>
  <number_of_arms>6</number_of_arms>
  <enrollment type="Actual">18</enrollment>
  <condition>Healthy</condition>
  <arm_group>
    <arm_group_label>Formulation A</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Formulation B</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Formulation C</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Formulation D</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Formulation E</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Formulation F</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>TRV734</intervention_name>
    <description>Subjects will be randomized to receive the oral TRV734 treatments on Days 1, 3, 5 and 7 in an open-label, 4-period, cross-over fashion. Days 2, 4, 6 and 8 are designated as washout days.</description>
    <arm_group_label>Formulation A</arm_group_label>
    <arm_group_label>Formulation B</arm_group_label>
    <arm_group_label>Formulation C</arm_group_label>
    <arm_group_label>Formulation D</arm_group_label>
    <arm_group_label>Formulation E</arm_group_label>
    <arm_group_label>Formulation F</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Healthy as determined by a responsible physician or trained qualified designee

          -  Males: 18 - 55 years inclusive at screening

          -  Capable of giving written informed consent

        Exclusion Criteria:

          -  Clinically significant conditions or history of fainting or syncope

          -  Medical or psychiatric illness that could interfere with the completion of treatment
             and follow up

          -  Major surgery within 4-weeks of screening

          -  Known difficulty with obtaining intravenous access

          -  History of sensitivity to the study medication, or intolerance to opioids, or a
             history of medication or other allergy that contraindicates their participation

          -  Use of prescription or non-prescription medications

          -  History of excessive alcohol use

          -  History of drug abuse within 6 months of screening

          -  Use of any illegal drug within 30 days of screening and throughout participation in
             the study

          -  History of smoking or use of nicotine containing products within 3 months of screening
             and throughout participation in the study

          -  Donation of blood or plasma 4 weeks prior to dosing

          -  Participation in a clinical trial and has received medication within 30 days

          -  Weight &lt;50 kg or BMI outside range of 18-32 kg/m2

          -  Positive for HIV antibody, hepatitis B virus surface antigen, or hepatitis C virus

          -  Unwillingness to abstain from sexual intercourse with a pregnant or lactating woman
             and, if engaging in sexual intercourse with a female partner of child-bearing
             potential, use a condom and spermicide, in addition to having their female partner use
             another form of contraception, and abstain from sperm donation
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>55 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <address>
        <city>San Antonio</city>
        <state>Texas</state>
        <zip>78209</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>November 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 4, 2015</study_first_submitted>
  <study_first_submitted_qc>April 3, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 8, 2015</study_first_posted>
  <last_update_submitted>November 17, 2015</last_update_submitted>
  <last_update_submitted_qc>November 17, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">November 18, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Healthy</keyword>
  <keyword>Male</keyword>
  <keyword>Pharmacokinetics</keyword>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

